Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 60.41M | 59.63M | 50.23M | 46.85M | 42.21M | 26.89M |
Gross Profit | 29.35M | 29.86M | 25.32M | 26.02M | 23.23M | 14.92M |
EBITDA | -60.69M | -67.81M | -34.02M | -31.82M | -20.94M | -11.01M |
Net Income | -18.44M | -72.21M | -36.40M | -31.74M | -22.12M | -6.94M |
Balance Sheet | ||||||
Total Assets | 191.70M | 159.48M | 202.98M | 242.59M | 260.91M | 178.83M |
Cash, Cash Equivalents and Short-Term Investments | 118.58M | 69.60M | 145.68M | 188.42M | 224.07M | 159.23M |
Total Debt | 4.43M | 6.61M | 5.95M | 16.47M | 20.85M | 21.86M |
Total Liabilities | 42.88M | 44.88M | 37.49M | 51.99M | 46.30M | 39.79M |
Stockholders Equity | 148.82M | 114.59M | 165.49M | 190.60M | 214.60M | 139.04M |
Cash Flow | ||||||
Free Cash Flow | -29.28M | -30.85M | -27.10M | -22.98M | -29.82M | 4.12M |
Operating Cash Flow | -28.65M | -30.25M | -25.06M | -20.93M | -29.08M | 4.13M |
Investing Cash Flow | 43.30M | -46.32M | -26.40M | -15.81M | -737.00K | -9.00K |
Financing Cash Flow | 285.00K | -376.00K | -15.94M | 1.18M | 94.72M | 137.19M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $289.05M | ― | -46.85% | ― | 14.65% | -86.36% | |
61 Neutral | $2.92B | -13.73 | -18.82% | ― | 8.57% | -1154.64% | |
55 Neutral | $4.71B | 59.25 | 4.38% | 0.64% | 10.36% | -78.26% | |
55 Neutral | $506.00M | -7.19 | -42.94% | ― | 23.13% | 46.62% | |
48 Neutral | $234.38M | -3.99 | 128.34% | ― | 45.50% | 53.07% | |
46 Neutral | $70.90M | -1.22 | -82.41% | ― | 18.24% | 4.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 4, 2025, 908 Devices announced the appointment of Dr. Brandi Vann, a former U.S. Department of Defense leader in nuclear, chemical, and biological defense, to its Board of Directors. This strategic move aligns with the company’s focus on enhancing its capabilities in public health, safety, and defense technology. Dr. Vann’s extensive experience is expected to bolster the company’s efforts in commercializing advanced chemical detection devices, while Jeff George, a veteran biopharma leader, has stepped down from the board as part of this strategic refocus.
The most recent analyst rating on (MASS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on 908 Devices stock, see the MASS Stock Forecast page.